IMC 3C5

Drug Profile

IMC 3C5

Alternative Names: IMC-3C5; LY-3022856

Latest Information Update: 28 Oct 2015

Price : $50

At a glance

  • Originator Circadian Technologies - Ludwig Institute for Cancer Research - Licentia (JV)
  • Developer ImClone Systems
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 01 Jul 2014 Eli Lilly completes a phase I trial in Solid tumours (late-stage disease, second-line therapy or greater) in the US (NCT01288989)
  • 15 May 2013 IMC 3C5 is still in phase I trials for solid tumours (late-stage disease, second-line therapy or greater) in USA
  • 06 Apr 2011 Phase-I clinical trials in Solid tumours (late-stage disease, second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top